IP Library Granted Patent US 7,422,746
Granted Patent B2
US 7,422,746 · App. 10/696,770 · Granted Sep 9, 2008

Chemically programmable immunity

Assignee: Altermune, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,422,746
App. No.
10/696,770
Granted
Sep 9, 2008
Kind
B2
Abstract

Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

Claims (26)

1. A method of increasing an immune response to a target in an individual comprising, administering to the individual an effective amount of a composition comprising

one or more immunity linkers, wherein the immunity linkers comprise at least one first binding site and at least one second binding site,

wherein the first binding site comprises a first polypeptide expressed by a first bacteriophage and

wherein the second binding site comprises a second polypeptide expressed by the first bacteriophage,

wherein the second binding site binds to the target and

wherein the individual has a pre-existing immune response to the first binding site, and

wherein the immune response is selected from a cellular immune response, and a humoral immune response, and an innate immune response.

2. The method of claim 1 , wherein the pre-existing immune response is induced by administering to the individual a universal immunogen comprising the first binding site.

3. The method of claim 1 , wherein the pre-existing immune response is induced by administering to the individual a universal immunogen that is an immunological equivalent of the first binding site.

4. The method of claim 1 , wherein the pre-existing immune response exists in the individual without administration of a universal immunogen.

5. The method of claim 1 , wherein the target is a pathogen.

6. The method of claim 1 , wherein the pre-existing immune response is induced by administering to the individual a universal immunogen comprising a second bacteriophage that expresses the first polypeptide.

7. The method of claim 6 , wherein the first bacteriophage and/or the second bacteriophage are each contained within one or more bacteria.

8. The method of claim 1 , wherein the individual is unable to mount an effective immune response to the target prior to administration of the immunity linker.

9. The method of claim 1 , wherein the composition comprises one or more different immunity linkers wherein the first binding sites differ in

a) their specificity for different immune response components, or

b) their affinity for the same immune response component.

10. The method of claim 9 , wherein the immune response component comprises an antibody.

11. The method of claim 1 , wherein the composition comprises one or more different immunity linkers comprising second binding sites that differ in

a) their specificity for different epitopes on the target, or

b) their affinity for the same epitope on the target.

12. A method of diverting a pre-existing immune response in an individual from an antigen to a target comprising, administering to the individual an effective amount of a composition comprising

one or more immunity linkers, wherein the linkers comprise at least one first binding site and at least one second binding site,

wherein the second binding site binds to the target and wherein the antigen comprises the first binding site,

wherein the first binding site comprises a first polypeptide expressed by a first bacteriophage and

wherein the second binding site comprises a second polypeptide expressed by the first bacteriophage.

Assignments (3)
CHANGE OF NAME Recorded Apr 2, 2019
From: ALTERMUNE TECHNOLOGIES LLC
To: CENTAURI THERAPEUTICS LIMITED
Reel/Frame 048772/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2010
From: ALTERMUNE LLC
To: ALTERMUNE TECHNOLOGIES LLC
Reel/Frame 024864/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2005
From: MULLIS, KARY B.
To: ALTERMUNE, LLC
Reel/Frame 016884/0946 →
Continuity (4)
Continuation In Part 1017804600 · Jun 21, 2002
Continuation PCTUS003517900 · Dec 21, 2000
Provisional Application 6017170700 · Dec 22, 1999
Related Publication 20040146515A1 · Jul 29, 2004